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ABSTRACT
The objective of the present study was to develop “once daily” 
sustained release tablets of metoclopramide hydrochloride 
by direct compression using hydroxypropyl methylcellulose 
(HPMC). No significant changes in terms of peak shifting, 
appearance or disappearance of peaks were noted with pure 
drug, polymers and mixtures. The developed sustained 
release and marketed immediate release of metoclopramide 
hydrochloride were appraised for physico-chemical parameters 
such as appearance, weight variation, thickness, hardness, 
friability and in vitro release study. Developed sustained release 
tablets of metoclopramide hydrochloride with respect to its 
physicochemical parameters and drug content are stable at long 
term storage conditions at 25oC and 60% RH, and accelerated 
conditions at 40oC and 75% RH for a period of six months. The 
in vitro drug release of Metoclopramide hydrochloride sustained 
release was compared with the marketed immediate release. The 
sustained release tablets of metoclopramide hydrochloride were 
well absorbed and the extent of absorption was higher than that 
of the marketed tablet. The Cmax and tmax data showed higher 
for immediate release compared to sustain release formulation. 
Developed Metoclopramide hydrochloride sustained release 
tablets demonstrated higher AUC, half-life and lower 
elimination rate constant values is indicative, that drug leftover 
in the body for extended period of time and showed signs of 
prolonged effect. The sustained and efficient drug delivery 
system developed in the present study will maintain plasma 
Metoclopramide hydrochloride levels better, which resolve the 
drawbacks related with the conventional therapy.
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1. INTRODUCTION
Metoclopramide hydrochloride is normally used for the 
gastrointestinal disorders. Metoclopramide hydrochloride 
has dopamine antagonist activity. Metoclopramide 
hydrochloride inhibits the central and peripheral effects 
of apomorphine, induces release of prolactin and causes 
a transient increase in circulating aldosterone levels. 
Metoclopramide hydrochloride enhances the motility 
of the stomach, pylorus and small intestine without 
stimulating gastric, biliary or pancreatic secretions. The 
gastrointestinal stimulant action is exerted peripherally, not 
by central stimulation of the vagus nerve, and it is blocked by 
anticholinergic drugs such as atropine [1-2].
Metoclopramide hydrochloride is commonly used for the 
treatment of nausea and vomiting. This drug is highly water 
soluble and is rapidly absorbed after oral administration. It has a 
short biological half life about 5 hours and is usually administered 
in a dose of 10 to 15 mg four times daily in order to maintain 
effective concentrations throughout the day [2]. Hydrophilic 
polymers are most commonly used in the formulation of 
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modified release dosage forms because of their elasticity 
to obtain enviable drug release profile, cost-effectiveness. 
HPMC is the foremost choice for formulation of hydrophilic 
matrix system, providing a robust mechanism, choice of 
viscosity grades, steady and reproducible release profiles, cost-
effectiveness, and utilization of conservative equipments. 
Various polymers like hydroxypropylmethylcellulose (HPMC), 
Carbopol, ethylcellulose, carboxymethylcellulose, etc. were 
tried. Individual grades of HPMC studied consist of methocel 
K15M and K100M.
Direct compression is a preferred because it offers the simple, 
most effective and less complex technique to manufacture 
tablets. The producer can be able to mix together an API with 
the excipient and the lubricant, followed by compression, 
which makes the product simple to process. No additional 
processing steps are required. Rationale in development of 
sustained release is to control of drug therapy is achieved, 
rate and extent of drug absorption can be tailored,frequency 
of dose can be reduced, to improve patient compliance, 
convenient, maximize the availability of drug with minimum 
dose and potency drug can be increased.
The developed sustained release and marketed immediate 
release were appraised for physico-chemical parameters 
such as appearance, weight variation, thickness, hardness, 
friability and in vitro release study. The in vitro drug release 
of Metoclopramide hydrochloride sustained release tablets 
was compared with the marketed immediate release tablet. 
The accelerated and intermediate stability study carried 
out for optimized formulations as per ICH guidelines]. The 
bioavailability study performed for marketed immediate 
release tablets containing 10 mg Metoclopramide 
hydrochloride and the developed sustained release tablets 
containing 5 mg Metoclopramide hydrochloride, and 
compared in terms of rate and extent of absorption.
Peak plasma concentration of Metoclopramide hydrochloride 
was 1 to 2 hours. And elimination half life was 2.5 to 5 hours. 
Due to short Cmax and half life drug is suitable for modified 
release formualtion. The purpose of this study was to develop 
an Metoclopramide hydrochloride (i.e. slow, medium & fast) 
sustained release (SR) tablets and to compare bioavailability 
with commercially available immediate release tablets (IR). 
In vitro and in vivo correlation study will be performed by 
using data of the in vitro and in vivo drug release.
2. MATERIALS AND METHODS
2.1 Materials
Metoclopramide hydrochloride and cisapride was a gift 
sample supplied from Adcock Ingram Healthcare Pvt. Ltd. 
(Bangalore, India). The HPMCK100M offered as a gift 
sample by Coloron Asia Pvt Ltd. (Goa, India). Avicel, Ethyl 
cellulose, Meagnesium sterate and talc were procured from 
local retailer.
2.2 Drug Excipient Compatibility Study
Compatibility between Metoclopramide hydrochloride 
and excipients were assessed by using differential scanning 
calorimetric and FTIR spectroscopy. The DSC thermo grams 
and FTIR spectra of pure drug, individual excipient and drug 
excipient mixtures were documented [3].
2.3 Preparation of Matrix Tablets[4-8]
Weighed amount of Metoclopramide hydrochloride, 
polymers (Hydroxypropylmethyl Cellulose [HPMC]/ Ethyl 
Cellulose [EC]), diluents (Microcrystalline Cellulose (MCC), 
and mixed by using glass pestle to get uniform mixture. The 
mixture then blended for 5 minutes with 2% magnesium 
stearate and 2% talc (E1, E2, E3) and 1% magnesium stearate 
and 1% talc (E4, E5, E6). Tablets were manufactured by direct 
compression of such mixtures were done by using Cad mach 
single punching machine with 10 mm bi-flat round shaped 
punches. The Metoclopramide hydrochloride sustained 
release formulation composition are presented in Table 1.
Table 1: Composition of Metoclopramide Hydrochloride Sustained Release Tablets
Formulation HPMC K100M Talc (2%) Magnesium Stearate (2%)
Avicel 
PH101 Talc (1%)
Magnesium Stearate 
(1%) Ethyl cellulose
E1 27.50 mg 1.65 mg 1.65 mg 50 mg - - -
E2 41.25 mg 1.93 mg 1.93 mg 50 mg - - -
E3 55.00 mg 2.20 mg 2.20 mg 50 mg - - -
E4 13.75 mg - - 50 mg 0.83 mg 0.83 mg 13.75 mg
E5 20.63 mg - - 50 mg 0.96 mg 0.96 mg 20.63 mg
E6 27.50 mg - - 50 mg 1.10 mg 1.10 mg 27.50 mg
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2.4 Tablet Evaluation
Formulated tablets were assessed for physicochemical 
properties such as appearance, weight variation, thickness, 
hardness, friability, drug content [9-10] and in vitro 
studies were carried out by using pH 1.2, 4.5, 5.5, 6.8 and 
7.4 (900 ml, 37±0.5 ˚C, 50 & 75 rpm) for 24 h using the 
USP XXIII basket apparatus (type II, paddle). A minimum 
of 6 tablets per batch were tested. At predetermined time 
intervals, 5 ml of samples withdrawn at 0.0, 0.5, 1.0, 1.5, 
2.0, 3.0, 4.0, 6.0, 8.0, 12.0, 18.0 and 24.0 hours, suitably 
diluted and spectrophotometrically assayed at 309 nm [11-
14]. Cumulative percentage of drug release calculated and 
compared. The percentage of release versus time data was 
estimated for the drug release kinetics.
2.5 Swelling Index
Optimized sustained release formulations were weighed 
and placed in a petri plate containing 25 ml of pH 6.4 
buffer solution for Metoclopramide hydrochloride. At 
predetermined time intervals at 1.0, 2.0, 3.0, 4.0, 6.0, 8.0 
10 hours, the tablets were removed from petri plate and 
absorbed buffer was removed by using filter paper [15]. 
The weight of the tablets were recorded after which they 
were placed in the perti plate for 10 hours. Swelling index 
calculated by using the following formula.
Swelling Index = (W1 – W2) x 100 (Equation 1)
Where, W1= weight of the polymer (Before swelling)
W2= weight of the polymer (After swelling)
2.6 Stability Study
Optimized Naproxen sodium and Metoclopramide 
hydrochloride sustained release formulation were packed 
in HDPE containers and incubated in the stability chamber 
at 25ºC 60%RH (Long term stability), 40ºC 75%RH 
(Accelerated stability) for stability studies. Samples were 
pulled from stability chamber at 1, 2, 3, 6 months intervals 
and evaluated for their physical properties like appearance, 
weight variation, thickness, hardness and drug content [16].
2.7 Release Kinetics
To know the mechanism of drug release for optimized 
formulation, the data were plotted according to zero-
order, first-order, Higuchi and Peppas equations to 
understand the mechanism of drug release and and to 
compare the differences in the release profile of optimized 
Metoclopramide hydrochloride sustained release.
2.8 In Vivo Bioavailability Study
The relative bioavailability of the developed Metoclopramide 
hydrochloride sustained release tablets and the marketed 
immediate release were assessed in a 6 subjects. The 
inclusion and exclusion criteria applied to all subjects, 
before admission, information on the study will be provided 
to the subjects, subjects are required to give their consent by 
signing informed consent form prior to participating in the 
study. All subjects were required to fast overnight for at least 
10 hours before dosing and for four hours after dosing. Six 
subjects were administered the developed Metoclopramide 
hydrochloride sustained release formulation (i.e. fast, 
medium & slow) and the marketed formulation with water. 
Subjects were not permitted to drink any fluids for one hour 
before dosing and until two hours post dose administration. 
The subjects were to remain ambulatory or seated upright 
for the first 2 hours after the study medication administered 
pre-dose sample will be taken within one hour prior to 
dosing. After dosing, samples will be taken at the following 
intervals 0.0, 0.33, 0.67, 1, 1.33, 1.67, 2, 3, 4, 6, 8, 10, 12, 
16, 18 and 24 hours post-dose [19]. Total 64 blood samples, 
so the total volume of blood drawn not exceeded 240 mL. 
After the 24 hour blood sample, the subjects are allowed 
to leave the facility. A washout period of at least 07 days, 
the procedure will be repeated. A high performance liquid 
chromatography mass spectrometric method for the 
estimation of Metoclopramide hydrochloride in human 
plasma was developed and validated by using cisapride 
as an internal standard. Sample preparation was done by 
using liquid-liquid extraction method. Chromatographic 
separation attained on a Eclipse XDB C18 (100 mm x 4.6 
mm, 3.5 µm) column by using a mobile phase of methanol 
and ammonium acetate buffer 5 mM (50:50 v/v). The flow 
rate was 1 mL/min and injection volume of 10 mL and run 
time was 3 minutes. The RT of analyte (Metoclopramide 
Hydrochloride) and internal standard was 1.1 and 2.1 
minutes. The method was validated over a concentration 
range of 0.532 ng/mL to 201.005 ng /mL for Metoclopramide 
hydrochloride. The plasma samples were analysed by using 
optimised chromatographic conditions [17-19].
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3. RESULTS
Precompression parameter plays a vital role in the 
preparation and optimization of tablets. The sustained 
release tablets were prepared by direct compression method. 
Pre-compression studies such as determinations of density, 
angle of repose, Carr’s index, Hausner’s ratio and effect of 
different concentrations of talc and magnesium stearate on 
the flow properties were performed. Carr’s Index (%) was 
found in the range of 13.31 to 14.91, Hausner’s Ratio was in 
the range of 1.15 to 1.17 for the all the formulation indicates 
the good flow property (C.I (%) 11 – 15 and Hausner’s Ratio 
1.12 – 1.18) and (angle of repose < 25). This indicates flow 
properties of the powder blend was within the acceptable 
limits. The granules of different formulations were 
evaluated for angle of repose, loose bulk density (LBD), 
tapped bulk density (TBD), and Carr`s index tabulated as 
shown in Table 2.
No significant changes in terms of peak shifting, appearance 
or disappearance of peaks were noted with pure drug, 
polymers and mixtures. The result revealed that there was 
no appreciable change in the melting endothermic peak of 
Metoclopramide hydrochloride in the presence of all the 
ingredients of sustained release formulation (185.53 ºC). 
The results indicate the absence of any chemical interactions 
between Metoclopramide hydrochloride and the excipients 
used. DSC thermo grams are presented as in Fig 1 A & B.
Table 2: Precompression Powder Properties of the Different Formulations of Metoclopramide Hydrochloride
Formulation LBD (g/ml) TBD (g/ml) Angle of Repose Carr’s Index (%) Hausner’s Ratio
Metoclopramide 
hydrochloride 0.52 0.71 35.97 26.77 1.36
E1 0.35 0.41 24.01 13.31 1.15
E2 0.37 0.43 22.16 14.91 1.17
E3 0.36 0.43 22.56 14.52 1.17
E4 0.37 0.43 23.23 14.14 1.16
E5 0.37 0.43 22.56 14.76 1.17
E6 0.36 0.42 23.46 14.12 1.16
Fig. 1 A. DSC Thermogram of Pure Metoclopramide Hydrochloride
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The characteristic bands of Metoclopramide hydrochloride 
were appeared in FTIR spectrum without any changes. 
The spectrum indicated as there is no chemical interaction 
between Metoclopramide hydrochloride and excipients. The 
spectrum clearly showed the functional groups bands which 
are related to Metoclopramide hydrochloride. The major 
band observed in 3396 cm-1 (N-H stretching), 2941 cm-1 
(C-H stretching),1632 cm-1 (C=O stretching),1539 cm-1 ( 
N-H bending ).679 C-Cl. No significant changes in terms 
of peak shifting, appearance or disappearance of peaks were 
noted with the drug and excipients. The IR spectra as in (Fig 
2 A& 2B).
Fig. 1 B. DSC Thermogram of Metoclopramide Hydrochloride and Excipients
Fig. 2 A. FTIR Spectrum of Pure Metoclopramide Hydrochloride
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Fig. 2 B. FTIR Spectrum of Metoclopramide Hydrochloride and Excipients
for 4 minutes (100 rotations) in the friabilator. The tablets 
were then dusted and re-weighed to determine the loss in 
weight. Friability was then calculated as percent weight loss 
from the original tablets. Friability values of all the batches 
are less than 1%. The drug content for all the formulations 
were found in the range of 96-102.45% found to be more 
than 90%.
3.2 In Vitro Drug Release Study
In vitro drug release study performed in multimedia 
dissolution to mimic the in-vivo condition. pH/buffer 
selection based on the exposure of drug from stomach to 
intestine/colon and to ensure the impact of pH changes on 
dissolution and release of drug substance for absorption 
(14-16). The in vitro drug release studies were conducted at 
different pH conditions (namely pH 1.2, 4.5, 5.5, 6.8, 7.4) at 
two different rpm i.e. 50 & 75 rpm to check the release and to 
select the optimize pH condition for the drug ().
3.1 Evaluation of Physicochemical Properties of 
Metoclopramide Hydrochloride Tablets
Twenty (20) tablets were individually weighed in grams (gm) 
by using analytical balance. The average weight deviation of 
20 tablet of each formula for Metoclorpamide hydrochloride 
was ± 1.054% which falls within the acceptable weight 
variation range of ± 5%. and and none deviated more than 
±10%11. Hence all the tablets were with in the limit for 
weight variation test. The thickness in millimeters (mm) 
was measured individually by using a vernier caliper and 
Thickness for the tablets was in the range of 3.15 to 4.23 
and showed little variation between the formulations 
manufactured. Tablet hardness was measured by using a 
Dr. Schridnger (model 8M) hardness tester. The crushing 
strength of the 10 tablets with known weight and thickness 
of each was recorded and reported. Hardness for tablets was 
in the range of 4.03-5.20 which falls above the limit of not 
less than 3.0 kg/cm2. Twenty (20) tablets were selected from 
each batch and weighed and tablets were rotated at 25 rpm 
Table 3: Physicochemical Evaluation of Compressed Tablets Containing Metoclopramide Hydrochloride
Formulations Hardness (kg/cm2) Weight Variation (gm) Thickness (mm) Friability (%)
E1 4.03 105.23 ± 2.36 3.15 <1%
E2 4.23 107.66 ± 1.16 3.46 <1%
E3 4.63 82.04 ± 4.57 3.89 <1%
E4 5.07 98.88 ± 1.80 3.17 <1%
E5 5.20 113.90 ± 1.05 3.56 <1%
E6 4.97 85.11 ± 0.671 4.23 <1%
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At pH 1.2 and 50 rpm, drug release was partial and a highest 
of about 31.98% was released within 24 hours for all the 
formulation. At pH 4.5, the drug release was very sluggish 
and 85.64% was released over the period of 24 hours. At pH 
5.5, about 94.50-99.23% of drug release observed and it was 
identical and slow within 24 hours. At pH 6.8 and 7.4 with 50 
rpm, although about 91.08-95.21% and 89.57-90.47% release 
of drug was observed. Hence pH 5.5 was optimized for all 
the developed formulations. The in vitro drug release profiles 
were not much changed when the rpm was increased to 50 
from 75. Based on the in vitro dissolution studies of E1 to 
E6 sustained release formulations in pH 5.5 and 50 rpm E2, 
E4 and E5 were considered as slow, medium and fast rate 
releasing formulations. The cumulative percentage of drug 
release are presented in Table. 4 and Fig. 3.
Table 4: Cumulative Percentage of Metoclopramide Hydrochloride Sustained Release and Marketed Release Tablet
Time
Slow (E2) Medium (E4) Fast (E5) Marketed (Drug Reference)
% Release
% Cumulative 
Release % Release
% Cumulative 
Release % Release
% Cumulative 
Release % Release
% Cumulative 
Release
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
0.50 12.60 12.60 15.40 15.40 19.20 19.20 75.69 75.69
1.00 17.70 17.77 20.50 20.59 24.20 24.31 82.96 83.38
1.50 26.10 26.20 31.70 31.81 34.30 34.43 92.98 93.44
2.00 32.90 33.05 38.50 38.68 42.60 42.79 97.78 98.30
2.50 39.60 39.78 49.70 49.91 53.50 53.74 98.76 99.30
3.00 48.00 48.22 57.40 57.68 61.00 61.30 99.65 100.20
4.00 53.90 54.17 63.40 63.72 67.70 68.04 99.82 100.37
6.00 58.10 58.40 69.30 69.65 76.10 76.48 99.90 100.45
8.00 66.50 66.82 76.20 76.59 79.40 79.82 100.01 100.57
10.00 73.30 73.67 80.50 80.92 85.20 85.64 100.05 100.61
12.00 78.30 78.71 86.50 86.95 89.40 89.87 100.06 100.62
18.00 85.10 85.54 92.50 92.98 95.30 95.80 100.18 100.74
24.00 91.80 92.27 95.00 95.51 98.60 99.13 100.21 100.77
Fig. 3. Cumulative Percentage of Metoclopramide Hydrochloride Sustained Release and Marketed Release Tablet
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3.3 Release Kinetics
The release kinetics of optimized Metoclopramide 
hydrochloride sustained release tablets are presented in the 
Table. 5 and graphical representation as mentioned in the 
Fig. 4 A, 4 B, 4 C & 4D.
Table 5: Release Kinetics of Optimized Metoclopramide Hydrochloride Sustained Release tablets (slow, medium & fast)
Formulation
Zero Order First Order Higuchi Korsmeyer-Peppas
r2 Ko (h–1) r2 K1 (h–1) r2 KH (h-1/2) r2 Slope (n)
E2 (Slow) 0.8075 3.2357 0.6026 0.0669 0.9391 19.511 0.9463 0.5212
E4 (Medium) 0.7301 3.2061 0.5465 0.0601 0.8877 19.694 0.9159 0.4837
E5 (Fast) 0.7168 3.1824 0.5545 0.0552 0.878 19.768 0.9200 0.4426
Fig. 4 A. Zero Order Release Profile of Metoclopramide Hydrochloride Sustained Release Tablets (slow, medium & fast)
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Fig. 4 B. First Order Release Profile of Metoclopramide hydrochloride Sustained Release Tablets (slow, medium & fast)
Fig. 4 C. Higuchi Kinetics Release Profile of Metoclopramide Hydrochloride Sustained Release Tablets (slow, medium & 
fast)
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Fig. 4 D. Korsmeyer-Peppas Kinetics Release Profile of Metoclopramide Hydrochloride Sustained Release Tablets (slow, 
medium & fast)
3.4 Stability Study
No significant change were observed for the developed 
sustained release tablets of Metoclopramide hydrochloride 
with respect to its physicochemical parameters as evident 
developed Metoclopramide hydrochloride sustained release 
tablets are stable at long term storage conditions at 25oC and 
60% RH, and accelerated conditions at 40oC and 75% RH for 
a period of six months.
3.5 Swelling Index
The swelling index calculated with respect to time and weight. 
As time increases, the swelling index increased, because 
weight gain by tablet increased proportionally with rate of 
hydration up to 10 hrs for all Metoclopramide hydrochloride 
SR tablets (i.e. E2 Slow release, E4 Medium release & E5 Fast 
release).
3.6 Bioavailability Study
The plasma concentration values obtained were calculated for 
pharmacokinetic parameters like Cmax, Tmax and AUC(0-
∞) by using Phoenix 6.4.0 version software. The Cmax and 
Tmax data showed higher for immediate release compare 
to sustain release formulation. The mean pharmacokinetic 
parameters for developed sustained release and marketed 
immediate release are summarized in Table 6 and graphical 
representation as in Fig. 5.
Table 6: Mean Pharmacokinetic Parameter of Metoclopramide Hydrochloride for Marketed Immediate Release and 
Sustained Release Tablet (fast, medium & slow)
Formulation Tmax (hr) Cmax (ug/mL) AUC(0-∞) (hr*ug/mL)
Immediate Release Tablet 1.11 49.06 273.694
Fast Sustained Release Tablet 0.89 48.433 214.506
Medium Sustained Release Tablet 0.89 48.004 238.671
Slow Sustained Release Tablet 1.002 48.366 230.834
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Fig 5: Mean Plasma Concentration-Time Profile of Metoclopramide Hydrochloride Immediate Release and Sustained 
Release (Slow, Medium, Fast) tablet
diffusion. The slope values obtained with Koresmeyer-
Peppas equation also appears to indicate a coupling of the 
diffusion and erosion mechanism-so-called inconsistent 
distribution and possibly indicates that the drug release 
is controlled by more than one method. The developed 
Metoclopramide hydrochloride sustained release tablets 
are stable at long term storage conditions at 25oC and 60% 
RH, and accelerated conditions at 40oC and 75% RH for a 
period of six months. The direct relationship was observed 
between swelling index and polymer concentration, and 
as polymer concentration increases, swelling index was 
increased. In vitro dissolution profiles of Metoclopramide 
hydrochloride showed a fast release compared to sustained 
release formulation. The developed tablets produced a 
higher AUC than the marketed immediate release product. 
Developed sustained release demonstrated high half-life 
and low elimination rate constant values is indicative, that 
drug leftover in the body for extended period of time and 
showed signs of prolonged effect. The prolonged effect 
of drug was further sustained by elevated values of mean 
residential time (MRT). Compared to previous study (Sayed 
IAR et al., 2009, Hasan EI et al., 2003) Metoclorpamide 
hydrochloride sustained release and immediate release 
tablet was compared by performing in vitro and in vivo 
4. DISCUSSION
The individual excipients did not show any characteristic 
peaks. The powder flow properties were evaluated for 
angle of repose, loose bulk density (LBD), tapped bulk 
density (TBD), and Car r`s Hausner’s ratio index. The 
good flow property (C.I (%) 11 – 15 and Hausner’s Ratio 
1.12 – 1.18) and (angle of repose < 25) were selected and 
used for the formulation. Weight variation of tablets fond 
with in the pharmacopeial limit. Thickness for the tablets 
demonstrated minor variation between the each batch of 
tablet. Hardness of the tablets were within the acceptance 
limit. Friability found less than 1% and drug content for the 
formulation were more than 90%. The in vitro drug release 
studies performed as per the USP method i.e. pH 6.8 pH 
condition at 50 rpm for developed sustained release and 
marketed immediate release formulation. The formulation 
with HPMC showed that an increase in polymer: drug ratio 
reduced the release rate. This was due to increase in polymer 
concentration caused an enlarge in the viscosity of the gel as 
well as the formation of a gel layer with a longer diffusion 
path. Drug release was found to follow Higuchi kinetics 
and slope (n) value obtained with all formulations ranged 
between 0.4426–0.5212. Since the slope values are near to 
0.5, the dominant mechanism for drug release is Fickian 
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correlation study to support biowaivers in cse of alteration 
in composition, equipments, batch sizes and manufacturing 
process.
5. CONCLUSION
The present study made successful preparation of once daily 
Metoclopramide hydrochloride sustained release matrix 
tablets. The optimized formulation was found to be stable 
at all the stability conditions. The developed formulation 
had superior bioavailability compared to the marketed 
formulation. The sustained release tablets of Metoclopramide 
hydrochloride were well absorbed and the extent of absorption 
was higher than that of the marketed tablet. The sustained 
and efficient drug delivery system developed in the present 
study will maintain plasma Metoclopramide hydrochloride 
levels better, which resolve the drawbacks related with the 
conventional therapy.
are required to confirm the results of present study.
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Metoklopramit Hidroklorür Hpmc Tabletlerinin Sürekli 
Salım Özelliği Gösteren Formülasyonlarını Hazırlanması ve 
Değerlendirilmesi
ÖZ
Bu çalışmanın amacı, hidroksipropil metilselüloz (HPMC) 
kullanılarak direkt basım yöntemi ile metoklopramid 
hidroklorür’ün “günde bir kez” kullanımı amacıyla sürekli 
salım özelliği gösteren tabletlerini geliştirmektir. Saf ilaç etken 
maddesi, polimerler ve karışımlar incelendiğinde pik kayması, 
piklerin varlığı veya kaybolması bakımından belirgin bir 
değişiklik kaydedilmedi. Metoklopramid hidroklorür içeren 
sürekli salınımı ve klinik kullanıma sunulmuş olan hemen salım 
özelliğine sahip tabletler, görünüş, ağırlık değişimi, kalınlık, 
sertlik, kırılganlık ve in vitro serbest salım gibi fiziko-kimyasal 
parametreler açısından değerlendirildi. Metoklopramid 
hidroklorür’ün sürekli salım özelliği gösteren tabletlerinin 
fizikokimyasal özellikleri ve ilaç içerikleri dikkate alındığında 
25⁰C’de ve %60 bağıl nem (RH) koşullarında ve 40°C’de ve 
%75 RH şartlarını içeren uzun süreli, hızlandırılmış altı aylık 
saklama koşullarında kararlıdır. Metoklopramid hidroklorür’ün 
sürekli salım tabletlerinden in vitro ilaç salınımı, piyasaya 
sürülmüş olan derhal salım özellikli tabletler ile karşılaştırıldı. 
Metoklopramid hidroklorür’ün sürekli salım tabletlerinin çok 
iyi emildiği ve emilim oranının pazarlanan tabletinkinden daha 
yüksek olduğu belirlendi. Sürekli salım formülasyonuna kıyasla 
Cmax ve tmax verileri derhal salım tabletleri için daha yüksek 
bulundu. Geliştirilen metoklopramid hidroklorür sürekli 
salınma tabletlerinin, yüksek AUC, yarılanma ömrü ve daha 
düşük eliminasyon hız sabiti değerleri göstermesi ilacın uzun 
süre vücutta kaldığını ve uzamış etki belirtileri gösterdiğini 
düşündürdü. Bu çalışmada, geliştirilen sürekli salım özellikli 
ilaç verme sisteminin, plazma metoklopramid hidroklorür 
düzeylerinin sağlanmasında daha iyi sonuç vereceği ve bu 
durumun da geleneksel tedavi ile ilgili sorunları ortadan 
kaldıracağı önerilmektedir.
Anahtar kelimeler: Metoklopramid hidroklorür; Sürekli 
salım; Günde bir kez, Hidroksipropilmetil selüloz; Dissolüsyon 
çalışması; Farmakokinetik çalışma.
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